RecruitingPhase 1NCT06911008

MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers

Studying Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mayo Clinic
Principal Investigator
Winston Tan, MD
Mayo Clinic
Intervention
Biospecimen Collection(procedure)
Enrollment
42 target
Eligibility
18 years · All sexes
Timeline
20252027

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06911008 on ClinicalTrials.gov

Other trials for Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome

← Back to all trials